key: cord-0737405-8sisiai4
authors: Magro, F; Rahier, J-F; Abeu, C; MacMahon, E; Hart, A; van der Woude, C J; Gordon, H; Adamina, M; Viget, N; Vavricka, S; Kucharzik, T; Leone, S; Siegmund, B; Danese, S; Peyrin-Biroulet, L
title: Inflammatory bowel disease management during the COVID-19 outbreak: The 10 do's and don'ts from the ECCO-COVID Taskforce
date: 2020-07-29
journal: J Crohns Colitis
DOI: 10.1093/ecco-jcc/jjaa160
sha: 3e349ae6fdc88a144d07abba681649dd631e073a
doc_id: 737405
cord_uid: 8sisiai4

Our knowledge on COVID-19 is changing and evolving rapidly, with novel insights and recommendations, almost on a daily basis. It behooves the medical community to provide updated information on a regular basis, on best practice to facilitate optimal care of infected patients and appropriate advice for the general population. This is particularly important in the case of patients with chronic conditions, such as Inflammatory Bowel Disease (IBD). In this paper, we compiled the existing evidence on the impact of COVID-19 in IBD patients and provide guidance and on the most appropriate care to adopt during the pandemic. Our review highlighted that IBD, per se, is not a risk factor for COVID-19. However, all IBD patients with symptoms should be tested for SARS-CoV-2 and the procedures for disease management shall be carefully adapted: i) in SARS-CoV-2 positive IBD patients, medical treatments should be re-evaluated (with particular focus on corticosteroids) always with the purpose of treating active disease and maintaining remission; ii) non-urgent surgeries and endoscopic procedures should be postponed for all patients; iii) online consultancy should be implemented; and iv) hospitalization and surgery should be limited to life threatening situations

At the end of 2019, a cluster of patients with pneumonia emerged in Wuhan, Hubei Province, China, with possible zoonotic origin. 1 This unidentified pneumonia was later found to be related to a novel coronavirus (CoV) 2 named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), by the International Committee on Taxonomy of Viruses (ICTV). 3 To prevent the use of inaccurate or stigmatizing names, the World Health Organization (WHO) proposed a standard format for the disease nomenclature:

COronaVIrus Disease-2019 . 4 SARS-CoV-2 is a single positive-stranded RNA virus enveloped in a lipid bilayer. The virus sneaks into the human body via the mucous membranes (mouth, nasal, ocular) and enters host cells through the binding of viral spike proteins (S-protein) to the human protein receptor angiotensin converting enzyme-2 (ACE2). 5 This receptor is abundant in lung, heart, kidney, adipose tissue, esophagus, stomach, bladder, ileum, and colon. 6, 7 Transmission of COVID-19 is efficient. Aerosol and fomite transmission of SARS-CoV-2 is plausible, since the virus can remain viable and infectious in aerosols for hours, and on surfaces up to days (depending on the inoculum shed). 8 In fact, the concentration of viral RNA in airborne samples is minimal or close to zero 9 , but it can be detected on fomites including plastic. 10 Transmission occurs from close contact and respiratory droplets, without evidence of airborne transfer 10 . Thus, people who are in close contact with patients, their family members or healthcare workers are part of the high-risk population. 11 The spread of SARS-CoV-2 identifed two important modes of disease transmission: i) local transmission, at each local epicenter; and ii) transmission via international travelers which favored the global spread of the infection, fueling COVID-19 pandemic. Large outbreaks were reported in closed communities and hospitals, raising the possibility of 'superspreading' events, as reported before in previous CoV outbreaks. 12 By May 2020, M a n u s c r i p t Manuscript Doi: 10.1093/ecco-jcc/jjaa160 the pandemic had affected almost 2 million people, worldwide, accounting for over 125,000 deaths, with the numbers rising sharply (Worldometer's COVID-19 data). 13 SARS-CoV-2 infection is associated with five different clinical courses: asymptomatic infection, mild to medium cases, severe cases, critical cases and death. 11 While highly transmissible, more than 80% of the patients have mild disease. 14 In the face of these challenging circumstances, gastroenterologists need to adapt priorities, reset standards of quality of care, and guide patients by providing relevant information.

In this context, the European Crohn's and Colitis Organization (ECCO) gathered a group of gastroenterologists, with particular interest in opportunistic infections, and infectious disease experts, to deliver guidance to physicians in the setting of gastrointestinal (GI) diseases during COVID-19 pandemic. The aim of the current paper is to provide health care professionals with understanding and knowledge of the optimal care we can provide to our patients, including those taking immunomodulatory treatment.

According to WHO 15, 16 and to the European Centre for Disease Prevention and Control (ECDC) 17 , social distancing, hand hygiene and respiratory etiquette should be adopted by all the population to prevent the spread of the infection. Hand hygiene is considered to be

Do's  Do avoid contact with infected people  Do avoid touching eyes, nose or mouth with unwashed hands  Do clean hands using soap and water or an alcohol-based solution  Do avoid crowded places  Do use face masks according to local policies  Do ensure flu vaccine for all non-vaccinated IBD patients  Do ensure pneumococcal vaccination for all non-vaccinated IBD patients  Do discourage travelling M a n u s c r i p t Such measures include routine cleaning of frequently used surfaces and objects (phones, tablets, keyboards), and minimizing the sharing of objects 17 (ECDC). Surgical masks may be used as an infection control measure or as a mitigation measure, in community settings, when used by individuals with respiratory symptoms but that did not seek medical attention yet. People at high risk of exposure include care providers with extensive face-to-face contact. A recent meta-analysis on influenza prevention suggested that N95 respirators should not be recommended to general public and low risk medical staff. 18 Travelling should be limited, for everyone, as much as possible, with the aim of reducing: i) acquisition of infection by travelers to areas or countries where community transmission is ongoing; ii) importation of cases from affected countries; and iii) transmission among travelers.

Patients with IBD, taking immunomodulatory therapy, have increased risk of influenza and pneumococcal disease. 19, 20 To avoid pulmonary comorbidities with influenza and pneumococcal disease during this outbreak, and next winter, all IBD patients should be vaccinated. Influenza and pneumococcal vaccination are recommended for the majority of patients with immune mediated disorders, including IBD. 21, 22 Since influenza infection rates can be reduced by annual vaccination, flu vaccine is recommended in all non-vaccinated IBD patients, and especially during COVID-19 pandemic. Although not numerous, some cases of influenza coinfection with SARS-CoV-2 have been described. 23, 24 During the next seasonal outbreak, SARS-CoV-2 and influenza are likely to occur simultaneously. Patients who have not been previously vaccinated for Streptococcus pneumoniae, should receive a dose of PCV13 followed by a dose of PPSV23, at least 8 weeks later. 25 So far, IBD patients have not shown increased susceptibility to COVID-19 [26] [27] [28] . This is clearly evidenced in very recent studies, in Spanish, French and Italian IBD cohorts studied, in which the risk of infection, associated mortality and incidence of COVID-19 were similar to those reported for the general population. 26, 27 A recent study from Wuhan, performed during the local outbreak of the disease, including 318 patients with IBD, did not report a single COVID-19 case. 28 However, all biological and immunomodulatory treatments were discontinued rendering interpretation difficult. 29 The therapeutic approach for these patients should instead consider the risk of viral infection weighed against the risk 2-Should we stop drugs in patients without symptoms suggestive of COVID-19 (not tested or tested negative)? Do's  Do continue immunomodulators  Do continue biologics  Do continue JAK inhibitors  Do reduce corticosteroids whenever possible  Do keep infusions in an infusion center whenever possible Don'ts  Don't reduce the dose of immunomodulators or biologics to prevent SARS-CoV-2 infection  Don't switch infliximab to adalimumab in a stable patient, unless it is not possible to provide intravenous infusions  Don´t assume that IBD patients are at increased risk of being infected Don't Know  Patients with IBD, who are exposed to SARS-CoV-2, have a higher risk of developing symptomatic or severe COVID-19 M a n u s c r i p t immunomodulators, anti-TNF therapy, anti-integrins and anti-Il12/23 were not associated with increased mortality. 33 Therefore, in balance, we believe that immunomodulatory drugs should be maintained in IBD patients without COVID-19 infection.

There are biological reasons to support why COVID-19 may not pose increased risk to IBD patients on immunomodulatory therapy. First, it has been suggested that the soluble form of ACE2 acts as a competitive binding partner for SARS-CoV-2 sequestring the virus, hindering binding to the virus's cell surface receptor, the full-length ACE2 protein. 34, 35 Elevated levels of ACE2 were measured in the plasma from patients with IBD 36 with evidence of limited infection progression and low susceptibility to infection. 37 The role of A c c e p t e d M a n u s c r i p t Manuscript Doi: 10.1093/ecco-jcc/jjaa160

ACE2 was also evidenced through the use of a chemical inhibitor of ACE2 (GL1001), that was able to reduce dextran sulfate sodium (DSS) colitis severity, in the mouse model, suggesting that ACE2 plays a pathogenic role in colitis. 35, 38 Second, tumor necrosis factor (TNF) inhibitors might be effective in reducing organ damage. 39 This effect is achieved through the decreased shedding of the ACE2 ectodomain (mediated by TNF-α-converting enzyme) which is essential for the penetration of SARS-CoV-2 into the cell. Third, as IFNγ and TNF production has been associated with severe SARS-CoV infection, inhibition of TNF has been proposed as a treatment for the cytokine release syndrome that can occur in some of these patients. 40 Fourth, mercaptopurine and 6-thioguanine have potential antiviral activity against MERS and SARS, at least in vitro. 41 Fifth, tacrolimus is a potent in vitro antiviral for human coronaviruses. 43 Sixth, most of the drugs used in IBD have a long elimination half-life and keep some activity even after treatment cessation. 44 Seventh, viral infections did not increase among IBD patients receiving ustekinumab and vedolizumab therapy. In addition, in a phase I clinical trial, the viral load of HIV patients on vedolizumab did not change significantly. In conclusion, the available data suggest that immunosuppressed patients are not at increased risk for severe disease and complications, compared with the general population.

In circumstances where it is not possible to safely run an infusion service, it may be reasonable to consider switching to sub-cutaneous alternatives. However, this practice must be used judiciously since elective switching from infliximab to adalimumab is associated with a loss of tolerance and efficacy within 1 year. 45 A c c e p t e d M a n u s c r i p t M a n u s c r i p t Manuscript Doi: 10.1093/ecco-jcc/jjaa160 admission (19%) and death (11%); although this data is currently unadjusted for age or comorbidity. 33 Concerning SARS-CoV-2 infection, steroids were not effective for the treatment of lung injury or shock. 48 However, short-term steroids (≤ 0.5-1 mg/kg for 7 days) may be beneficial to control overwhelming inflammation and cytokine-related lung injury, particularly in severe forms of ARDS. [49] [50] [51] Data on low-dose and short-term steroids, budesonide and beclomethasone therapy are not currently available.

The first analysis of the SECURE-IBD data also identified 5-ASAs as a risk for severe VZV, HSV), mostly in patients exposed to thiopurines. 53 This can be related to the ability of azathioprine/6-mercaptopurine and tofacitinib to reduce the number of activated T cells and affect T-cell activation and effector function. 35 Tofacitinib has also been associated with viral infections (VZV) 54 and demonstrated inhibition of interferon-α production in vitro. 55 The decision to pharmacologically immunosuppress a patient with COVID-19 remains difficult. The possible beneficial effects in reducing inflammation should be carefully weighed against the potential deleterious impairment of anti-microbial immunity.

A c c e p t e d M a n u s c r i p t The maximal viral shedding of SARS-CoV-2 occurs in the early stages of infection, meaning that spreading from asymptomatic patients is a reality. In hospitals and clinics caring for a large number of COVID-19 patients, the rate of infection is high among health

Do's  Do implement screening procedures for suspected COVID-19 in all patients  Do implement measures to minimize crowding  Do implement at least 2m distance between chairs  Do impose the use of surgical face masks in all patients  Do continue biologics at regular intervals and doses Don'ts  Don't switch infliximab to adalimumab in stable patients unless it is not possible to provide intravenous infusions  Don't allow accompanying persons inside the hospital workers. 71 In IV infusion clinics, the first measure is to identify the patients who are possibly infected, since the approach and safety requirements will be different. Thus, symptomatic (fever, cough, fatigue, myalgia, expectoration, diarrhea, and loss of sense of smell or taste) or suspected (contact with a positive person) patients should be promptly tested and submitted to protective measures. The use of masks, in patients attending hospitals, is highly recommended, even in those without symptoms. 72 populations. In fact, faecal calprotectin levels showed a significant correlation with endoscopic extent, mucosal healing, and histological activity. 77, 78 Moreover, non-invasive imaging, such as ultrasonography, is essential for diagnosis and monitoring because it is a low risk procedure with the advantage of providing a rapid assessment of disease activity (location, extension, inflammation, and presence of complications like fistula, strictures or intrabdominal abscesses). 79 A c c e p t e d M a n u s c r i p t Manuscript Doi: 10.1093/ecco-jcc/jjaa160

In the case of patients enrolled in clinical trials before the outbreak, the sponsors can be asked to: i) postpone non-necessary follow-up visits or to replace them by virtual clinics; ii) identify local labs that can guarantee the regular lab tests required by the protocol; iii) manage home delivery of study drugs, mainly those of oral and subcutaneous administration. In this scenario, patients would go to the hospital only for key visits (end of induction, re-randomization, end of study) and to receive intravenous drugs, when these cannot be suspended. The administration of intravenous drugs can also be adapted, mainly regarding dose intervals. For instance, infliximab administration can be postponed to every 10 weeks. 80 Regarding vedolizumab, the GEMINI trial showed that patients randomized to placebo can maintain remission up to week 24. Therefore, postponing vedolizumab 4-8 weeks may be reasonable. However, maintaining the original schedule remains the best strategy in most cases.

IBD patients on immunomodulators do not seem to have a higher risk of infection than the rest of the population. However, due to disease specificities and possible side effects of the treatment, avoidance of SARS-CoV-2 requires an additional set of precautions.

Thus, patients should take extra protective measures, over and above those of the general population. Some societies use the concept of "stringent social distancing" and "shielding", with measures ranging from avoidance of crowded places to advice to not leave the house Endoscopy should be performed in a negative-pressure room, if possible, in accordance with the guidelines for infection control in endoscopy. 85, 86 In addition, the staff of the endoscopy department should follow standardized precautions. 12 SARS-CoV-2 is easily inactivated by many common disinfectants and no additional approach should be implemented to clean and disinfect the endoscope. 87 Even so, due to the risk of aerosolization, the room should be kept empty for at least for 1 hour before the next procedure in the absence of negative pressure, and for 30 minutes in the case of a negative-pressure room. 88 The basic protection requirements of the medical staff, in the endoscopy centre, should reach Biosafety level 2 (wearing of disposable gowns, N95

A c c e p t e d M a n u s c r i p t Emergency surgery is required in life-threatening situations, such as bowel perforation, closed loop, or medically refractory acute severe colitis. Conversely, non-urgent surgery should be postponed to protect patients and healthcare workers, and facilitate the management of healthcare resources, in times of scarcity of staff and material. [89] [90] [91] Non-elective surgery is indicated for invasive colorectal cancer/high-grade dysplasia, intractable stenosis, and abdominal/perianal abscesses not amenable to medical/interventional management. 92 Perioperative complexity should be minimized, including liberal use of terminal ostomy instead of a high-risk anastomosis, and drainage procedures, with or without antibiotics, instead of complex surgery. 92 Keeping track of deferred surgeries is the key to provide responsible surgical care after the pandemic.

Owing to the paucity of symptoms in the majority of COVID-19-positive patients and to the surgical morbidity reported during viral incubation (mortality 20.5%, ICU requirement

Do's  Do emergency surgery in life-threatening situations  free bowel perforation  closed loop obstruction  acute severe colitis refractory to medical treatment  active bleeding not amenable to interventional therapy  Do non-elective surgery as soon as possible  invasive colorectal cancer, high-grade dysplasia  intractable stenosis failing medical management  penetrating luminal disease resistant to medical therapy  perianal abscesses  Do postpone surgery in uncomplicated IBD  Do test all IBD patients with SARS-CoV-2-PCR before any surgery  Do use N95 respirators as a minimal requirement for surgery Don'ts  Don't perform non-urgent IBD surgery A c c e p t e d M a n u s c r i p t Manuscript Doi: 10.1093/ecco-jcc/jjaa160 44.1%), it is mandatory to test all patients for SARS-CoV-2 before surgery. 89, 93, 94 When rapid PCR tests are unavailable, chest CT can be the diagnostic. If neither testing nor imaging is available, all patients must be considered positive. 92 At surgery, the risk of aerosolization is high and contamination with body fluids is a concern. 93 To date, infectious virus was found in airway, blood, and feces. 61 Aerosol formation is potentiated by tissue dissection with energy devices, while concentration of abdominal aerosol is inherent to laparoscopy. [95] [96] [97] Consequent use of PPE is mandatory, including face shield/googles, N95 mask, and proper donning and doffing. 95 The number of staff should be minimized and negative pressure operating rooms should be preferred.

Scientific societies have issued conflicting statements regarding the use of laparoscopy, with no firm contraindication in the COVID-19 era. Avoidance of laparoscopy is thus debatable, as open surgery will translate in additional morbidity and resource utilization.

Low energy setting and pneumoperitoneum pressure, avoidance of 2-way insufflators, closed circulation with efficient filtration of pneumoperitoneum, and gentle desufflation are advised. 98 

In conclusion, the existing evidence shows that IBD is not a risk factor for COVID-19.

However, medical treatments should be re-evaluated in SARS-CoV-2 positive IBD patients and corticosteroid therapy should be re-evaluated regardless of symptoms. A goal should be to treat active disease and maintain remission, while adopting the same protective measures as the general population. In addition, non-urgent surgeries and endoscopic procedures should be postponed.

A c c e p t e d M a n u s c r i p t

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

A Novel Coronavirus from Patients with Pneumonia in China

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

COVID-19) and the virus that causes it

A novel coronavirus outbreak of global health concern

ACE2: from vasopeptidase to SARS virus receptor

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection

Katrin Zwirgl CW. Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travelassociated transmission cluster

Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1

Pathogenesis, and Control of COVID-19

The daily impact of COVID-19 in gastroenterology

Worldometer's real-time data on COVID-19

Management of IBD during the COVID-19 outbreak: resetting clinical priorities

Non-pharmaceutical public health measures for mitigating the risk and impact of epidemic and pandemic influenza

COVID-19) advice for the public

Effectiveness of N95 respirators versus surgical masks against influenza: A systematic review and metaanalysis

Increased Risk of Influenza and Influenza-Related Complications Among 140,480 Patients With Inflammatory Bowel Disease

Inflammatory Bowel Disease Patients Are at Increased Risk of Invasive Pneumococcal Disease: A Nationwide Danish Cohort Study 1977-2013

Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease

2019 update of EULAR recommendations for vaccination in adult patients with

autoimmune inflammatory rheumatic diseases

The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan

Paniz Mondolfi AE. Co-infection in SARS-CoV-2 infected Patients: Where Are Influenza Virus and Rhinovirus/Enterovirus?

Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices

Novel Coronavirus Disease (COVID-19) in patients with Inflammatory Bowel Diseases

Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts

Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China

Inflammatory bowel diseases and COVID-19: the invisible enemy

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical Characteristics of Coronavirus Disease 2019 in China

Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic

COVID-19 spike-host cell receptor GRP78 binding site prediction

Covid-19 and immunomodulation in IBD

Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?

Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?

Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate

Regulation of interferon production as a potential strategy for COVID-19

Cell Responses to Whole SARS Coronavirus in Humans

Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir

Management of Patients with Crohn's Disease and Ulcerative Colitis During the COVID-19 Pandemic: Results of an International Meeting

Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial

Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia

On the use of corticosteroids for 2019-nCoV pneumonia

Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines

A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn's Disease

JAK-inhibitor tofacitinib suppresses interferon alfa production by plasmacytoid dendritic cells and inhibits arthrogenic and antiviral effects of interferon alfa

Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak

Inflammatory bowel disease management during the COVID-19 outbreak: a survey from the European Crohn's and Colitis Organization (ECCO)

Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection

Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome

Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

Virological assessment of hospitalized patients with COVID-2019

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

Laboratory testing of SARS-CoV, MERS-CoV, and SARS-CoV-2 (2019-nCoV): Current status, challenges, and countermeasures

Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases

Rapid detection and monitoring of human coronavirus infections

Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)

Clinical characteristics of 80 hospitalized frontline medical workers infected with COVID-19 in Wuhan

Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review

Covid-19: should the public wear face masks?

Quality of care standards in inflammatory bowel diseases: a European Crohn's and Colitis Organisation (ECCO) position paper. J Crohn's Colitis 2020

Efficacy of Home Telemonitoring versus Conventional Follow-up: A Randomized Controlled Trial among Teenagers with Inflammatory Bowel Disease

Is home monitoring of inflammatory bowel disease feasible? A randomized controlled study

Review article: faecal calprotectin and histologic remission in ulcerative colitis

Accuracy of Faecal Calprotectin and Neutrophil Gelatinase B-associated Lipocalin in Evaluating Subclinical Inflammation in UlceRaTIVE Colitis-the ACERTIVE study

Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period

De-escalation of Infliximab Maintenance Therapy from 8-to 10-week Dosing Interval Based on Faecal Calprotectin in Patients with Crohn's Disease

COVID-19: identifying patients for shielding

British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic

Low risk of covid-19 transmission in GI endoscopy

Rates of infection after colonoscopy and osophagogastroduodenoscopy in ambulatory surgery centres in the USA

Reprocessing of flexible endoscopes and endoscopic accessories used in gastrointestinal endoscopy: Position Statement of the European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastroenterology Nurses and Associates (ESGENA) -Up

ASGE guideline for infection control during GI endoscopy

Human Coronaviruses: Insights into Environmental Resistance and Its Influence on the Development of New Antiseptic Strategies

COVID-19) outbreak: what the department of endoscopy should know

SAGES and EAES recommendations regarding surgical response to COVID-19 crisis

Global guidance for surgical care during the COVID-19 pandemic

Managing COVID-19 in Surgical Systems

International Organization for the Study of Inflammatory Bowel Disease Recommendations for Surgery in Patients with Inflammatory Bowel Disease During the COVID-19 Pandemic

COVID-19 Outbreak and Surgical Practice

Protecting Surgical Teams During the COVID-19 Outbreak

COVID-19 & the General Surgical Department -Measures to Reduce Spread of SARS-COV-2 Among Surgeons

Minimally Invasive Surgery and the Novel Coronavirus Outbreak: Lessons Learned in China and Italy

What Is the Appropriate Use of Laparoscopy over Open Procedures in the Current COVID-19 Climate?

A c c e p t e d M a n u s c r i p t